iTeos Therapeutics, Inc. (ITOS)
| Market Cap | 1.46B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 24.35M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $41.49 |
| Previous Close | $41.58 |
| Change ($) | -0.09 |
| Change (%) | -0.22% |
| Day's Open | 41.83 |
| Day's Range | 41.07 - 42.66 |
| Day's Volume | 130,764 |
| 52-Week Range | 17.50 - 43.69 |
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 17, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and deve...
About ITOS
Iteos Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.
| Industry Biotechnology | IPO Date Jul 24, 2020 |
| CEO Dr. Michel Detheux | Employees 55 |
| Stock Exchange NASDAQ | Ticker Symbol ITOS |
Analyst Forecasts
According to 5 analysts, the average rating for ITOS stock is "Strong Buy." The 12-month stock price forecast is 43.60, which is an increase of 5.09% from the latest price.